肿瘤细胞治疗研究
英文原题：Immunotherapy for hepatocellular carcinoma.
其高复发率和缺乏有效控制药物导致5年生存率仅为约10%。
肝细胞癌（HCC）是全球癌症相关死亡的主要原因之一。其高复发率和缺乏有效控制药物导致5年生存率仅为约10%。HCC是一种受免疫系统调控的肿瘤。近年来，免疫治疗在实体瘤治疗中取得了重大突破。多种免疫疗法，如免疫检查点抑制剂（ICIs），包括联合治疗，在临床应用和研究中均显示出有前景的治疗效果。其他免疫疗法，如过继性细胞治疗和溶瘤病毒，也在不断涌现，为解决HCC的长期生存问题带来了希望。本文综述了当前常用的免疫治疗策略及最新研究进展，以供参考。
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide. Its high recurrence rate and lack of effective control drugs result in a 5-year survival rate of only about 10%. HCC is a tumor regulated by the immune system. Significant breakthroughs have occurred in treating solid tumors with immunotherapy in recent years. Various immunotherapies, such as immune checkpoint inhibitors (ICIs), including combination therapies, have demonstrated promising therapeutic effects in both clinical applications and research. Other immunotherapies, such as adoptive cell therapies and oncolytic viruses, are also emerging, offering hope for addressing long-term survival issues in HCC. This article reviews current commonly used immunotherapy strategies and the latest research findings for reference.
MEMBER ACCOUNT
登录成功会直接打开下一页。
